Targeted Alpha-Therapy Using [Bi-213]anti-Cd20 as Novel Treatment Option for Radio- And Chemoresistant Non-Hodgkin Lymphoma Cells

Oncotarget - United States
doi 10.18632/oncotarget.817
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Bendamustine-Based Therapy as First-Line Treatment for Non-Hodgkin Lymphoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2014English

Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates

Molecules
Organic ChemistryMolecular MedicineAnalytical ChemistryTheoretical ChemistryPharmaceutical ScienceMedicineDrug DiscoveryChemistryPhysical
2015English

Improving the Treatment of Non-Hodgkin Lymphoma With Antibody-Targeted Radionuclides

Cancer
Cancer ResearchOncology
2010English

CD30-targeted Oncolytic Viruses as Novel Therapeutic Approach Against Classical Hodgkin Lymphoma

Oncotarget
Oncology
2018English

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2012English

Antibody-Targeted Paclitaxel Loaded Nanoparticles for the Treatment of CD20+ B-Cell Lymphoma

Scientific Reports
Multidisciplinary
2017English

A Novel Immunomodulatory and Molecularly Targeted Strategy for Refractory Hodgkin’s Lymphoma

Oncotarget
Oncology
2013English

Novel Treatment Strategies for Patients With Relapsed Classical Hodgkin Lymphoma

Blood Reviews
OncologyHematology
2010English

Non-Hodgkin Lymphoma

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy